Details of the Drug

General Information of Drug (ID: DMR9TF1)

Drug Name
Bimekizumab
Indication
Disease Entry ICD 11 Status REF
Plaque psoriasis EA90.0 Approved [1]
Psoriatic arthritis FA21 Phase 2 [2]
Affected Organisms
Humans and other mammals
ATC Code
L04AC21: Bimekizumab
L04AC: Interleukin inhibitors
L04A: IMMUNOSUPPRESSANTS
L04: IMMUNOSUPPRESSANTS
L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Cross-matching ID
UNII
09495UIM6V
DrugBank ID
DB12917
TTD ID
D0WJ5M
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Cytokine ML-1 (IL17F) TT2B6PS IL17F_HUMAN Not Available [2]
Interleukin-17 (IL17) TTG0MT6 IL17_HUMAN Not Available [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Plaque psoriasis
ICD Disease Classification EA90.0
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Interleukin-17 (IL17) DTT IL17A 2.91E-02 -0.16 -0.69
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761151
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)